A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2 R ,6 R )‐Hydroxynorketamine in Healthy Volunteers
Clinical Pharmacology & Therapeutics · 2024-11 · 116 (5) · 1314-1324
DOI: 10.1002/cpt.3391 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 25.07.2024. Verfasst von Shruti M Raja und 40 weiteren Autor:innen. Beteiligte Einrichtung: Duke Early Phase Research Unit, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Ketamine, Healthy Volunteers, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BLRD VA, Intramural NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
( R , S )‐Ketamine (ketamine) is a dissociative anesthetic that also possesses analgesic and antidepressant activity. Undesirable dissociative side effects and misuse potential limit expanded use of ketamine in several mental health disorders despite promising clinical activity and intensifying medical need. (2 R ,6 R )‐Hydroxynorketamine ( RR‐ HNK) is a metabolite of ketamine that lacks anesthetic and dissociative activity but maintains antidepressant and analgesic activity in multiple preclinical models. To enable future assessments in selected human indications, we report the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RR‐ HNK in a Phase 1 study in healthy volunteers (NCT04711005). A six‐level single‐ascending dose (SAD) (0.1–4 mg/kg) and a two‐level multiple ascending dose (MAD) (1 and 2 mg/kg) study was performed using a 40‐minute IV administration emulating the common practice for ketamine administration for depression. Safety assessments showed RR‐ HNK possessed a minimal adverse event profile and no serious adverse events at all doses examined. Evaluations of dissociation and sedation demonstrated that RR‐ HNK did not possess anesthetic or dissociative characteristics in the doses examined. RR‐ HNK PK parameters were measured in both the SAD and MAD studies and exhibited dose‐proportional increases in exposure. Quantitative electroencephalography (EEG) measurements collected as a PD parameter based on preclinical findings and ketamine's established effect on gamma‐power oscillations demonstrated increases of gamma power in some participants at the lower/mid‐range doses examined. Cerebrospinal fluid examination confirmed RR‐ HNK exposure within the central nervous system (CNS). Collectively, these data demonstrate RR‐ HNK is well tolerated with an acceptable PK profile and promising PD outcomes to support the progression into Phase 2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Early Phase Research Unit, Duke University School of Medicine, Durham, North Carolina, USA.
- Argenx BV, Ghent, Belgium.
- Fortrea Inc., Durham, North Carolina, USA.
- Quotient Sciences, Alnwick, UK.
- Labcorp Bioanalytical Services, Indianapolis, Indiana, USA.
- National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA.
ORCID-Profile: Shruti M Raja, Alfredo R Sancho, Maryland Pao, Jessica R Gilbert, Craig J Thomas
Förderung
- BLRD VA
- Intramural NIH HHS
- NIMH NIH HHS
Zitieren
APA
Raja, S. M., Guptill, J. T., Mack, M., Peterson, M., Byard, S., Twieg, R., Jordan, L., Rich, N., Castledine, R., Bourne, S., Wilmshurst, M., Oxendine, S., Avula, S. G. C., Zuleta, H., Quigley, P., Lawson, S., McQuaker, S. J., Ahmadkhaniha, R., Appelbaum, L. G., …, & Thomas, C. J. (2024). A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2 R ,6 R )‐Hydroxynorketamine in Healthy Volunteers. Clinical Pharmacology & Therapeutics, 116(5), 1314-1324. https://doi.org/10.1002/cpt.3391
Vancouver
Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, et al. A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2 R ,6 R )‐Hydroxynorketamine in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 2024;116(5):1314-1324. doi:10.1002/cpt.3391
BibTeX
@article{Raja2024,
author = {Raja, Shruti M and Guptill, Jeffrey T and Mack, Michelle and Peterson, Marni and Byard, Stephen and Twieg, Robert and Jordan, Lynn and Rich, Natalie and Castledine, Richard and Bourne, Samuel and Wilmshurst, Martin and Oxendine, Sarah and Avula, Satya G C and Zuleta, Helen and Quigley, Paul and Lawson, Sheila and McQuaker, Stephen J and Ahmadkhaniha, Reza and Appelbaum, Lawrence G and Kowalski, Kevin and Barksdale, Chineta T and Gufford, Brandon T and Awan, Asaad and Sancho, Alfredo R and Moore, Max C and Berrada, Karim and Cogan, Gregory B and DeLaRosa, Jesse and Radcliffe, Jeanne and Pao, Maryland and Kennedy, Michelle and Lawrence, Quentin and Goldfeder, Lisa and Amanfo, Leslie and Zanos, Panos and Gilbert, Jessica R and Morris, Patrick J and Moaddel, Ruin and Gould, Todd D and Zarate, Carlos A and Thomas, Craig J},
title = {A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2 R ,6 R )‐Hydroxynorketamine in Healthy Volunteers},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {116},
number = {5},
pages = {1314--1324},
doi = {10.1002/cpt.3391}
}
EUVIMED